INFORMATION DISCLOSURE

PTO/SB/06a (01-10)
Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless if contains a valid OMS control number

10783640

2004-02-20

P P Silkatis

STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)								
			Art Unit			3626		
			Examiner Name Sorey		7, Robert A. 7135USO3			
				Attorney Docket Number				
	U.S.PATENTS Remove							
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of of cited D		tee or Applicant ent	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1							
If you wis	h to add	additional U.S. Pate	nt citatio	n information p	lease click	the Ad	dd button.	Add

Application Number

Filing Date

h to add a	dditional U.S. Pater	t citatio	n information pl	lease click the Add button.	Add
		U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Cite No	Publication Number			Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1	20020040282	A1	2002-04-04	Bailey et al.	
2	20030140929	A1	2003-07-31	Wilkes et al.	
	Cite No	Cite No Publication Number	U.S.P.  Cite No Publication Number Kind Code <sup>1</sup> 1 20020040282 A1	U.S.PATENT APPLI	1 2002:040282 A1 2002:04-04 Bailey et al.

If you wish to add additional U.S. Published Application citation information please click the Add button. Add FORFIGN PATENT DOCUMENTS Remove Pages Columns Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Applicant of cited T5 Initial\* No Number<sup>3</sup> Code2 i Code<sup>4</sup> Date Passages or Relevant Document Figures Appear

NON-PATENT LITERATURE DOCUMENTS

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

Remove

#### 

Examiner Initials*	Cite No							
	1	General-Purpose Influsion Pumps, Health Devices, October 1, 2002, pp. 353-387, Vol. 31, No. 10, ECRI Institute.						
	2	EW J. A. ET AL, Using Innovative Technologies to Set New Safety Standards for the Infusion of Intravenous cations, Hospital Pharmacy, November 1, 2002, pp. 1179-1189, Vol. 37, No. 11, Lippincott, Philadelphia, PA.						
	3	KOWSKI ET AL, Using Technology to Improve Medication Safety in the Newborn Intensive Care Unit, Advances constal Care, December 1, 2001, pp. 70-83, Vol. 1, No. 2, W. B. Saunders.						
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

16e Knr. Oxford 1.08/TO Peter Documents at war USETO.QDL/ or MREP 961.64. 2 Enter office that issued the document, by the un-exister oxide (MIPO Standard 313). 3 "For dispresse parter document, the origination of the year of the signs of the Emperor may preced to see self unched of the parter document."

\*Indirect document by the appropriate symbols as indicated on the document under WIPO Standard 37.16 if possible. 5 Applicant is to place a check mark there if Empirish tanguages treatised in salt stude.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10783640	
Filing Date		2004-02-20	
First Named Inventor	R.P.	P. Silkartis	
Art Unit		3626	
Examiner Name Sorey		r, Robert A.	
Attorney Docket Number		7135US03	

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.37(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/MRC Reg. No. 37298/	Date (YYYY-MM-DD)	2011-08-15
Name/Print	Michael R. Crahh	Registration Number	37298

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.